The FDA's grant of a seven-year orphan drug exclusivity for TARPEYO to Calliditas Therapeutics AB is a significant positive development. This exclusivity period protects TARPEYO from direct competition in the U.S. market, potentially leading to sustained revenue from this product. The exclusivity until December 2030 provides a long-term competitive advantage, likely positively impacting investor sentiment and the stock price in the short term.